Kornimate/medical-research-clean huggingface dataset:
efficacy study of prophylactic ibuprofen versus placebo on pain relief and success rates of medical abortion

Conditions: Pain; Pregnancy

Summary: in the current study, we want to evaluate the prophylactic use of ibuprofen versus a placebo for medical abortion by mifepristone and misoprostol, at a gestational age of up to 7 weeks, in regard to the effect on pain relief and the overall procedure success. expected results: the prophylactic use of nsaids could offer significant pain relief and thereby a reduction in the need for additional pain relievers compared to the placebo, without interfering with the outcome of medical abortion


Eligibility criteria:
inclusion criteria: * good general health * pregnancy of up to 7 weeks gestation. * approval from the ministry of health committee for termination of pregnancy after an intrauterine pregnancy was demonstrated by an ultrasound exam. * subjects that provided informed consent and agree to comply with all study procedures. exclusion criteria: * known allergy to mifepristone, misoprostol, paracetamol or nsaids. * severe anemia. * drug or alcohol abuse * known abnormal liver function (liver function tests greater than 1.5 times upper range of normal). * known abnormal renal function (serum creatinine \> 1.5 mg/dl). * abnormal blood tests * exclusionary health problems contraindicating mifepristone included adrenal disease; sickle cell anemia; severe liver, respiratory, or renal disease; and blood clotting defect. * chronic disease * patient is participating currently in another clinical trial

Keywords: pain after abortion abortion
determining the effect of vitamin d, dyslipidemia and microvascular in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study looked at the effect of vitamin d levels on the complications of type 2 diabetes and the fat profile of patients with diabetes.participants in this study were divided into two groups. one group included participants with vitamin d deficiency and the other group did not.the first group receives 50,000 units of oral vitamin d 3 daily for up to 8 days.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes * having conscious satisfaction exclusion criteria: * patients with a history of gastrointestinal surgery * patients with a history of renal failure * patients with a history of vitamin d intake and calcium-containing compounds * patients with a history of liver disease
research study to investigate the effect of nnc0174-0833 on a birth control pill in women who are not able to become pregnant

Conditions: Overweight; Obesity

Summary: the study looks at how the study medicine affects the level in the blood of a birth control pill. the study also looks at how the study medicine affects the duration of emptying of the stomach. participants will get 1 injection of study medicine once a week for 12 weeks by a study nurse at the clinic. the study medicine is injected with a thin needle in a skin fold in the stomach. in addition, participants will get 1 birth control pill per day for 8 days before the first dose of the study medicine and again after 10 weeks of dosing with the study medicine. participants will also get a dose of acetaminophen before the first dose of the study medicine and again after 10 weeks of dosing with the study medicine. acetaminophen is a mild painkiller but used here to assess the emptying of the stomach. the study will last for about 9 months, but participants will only be in the study for about 6 months. participants will have 17 clinic visits with the study staff and some will be overnight visits. there will also be 3 phone calls with the study staff. at all visits, participants will have blood drawn along with other clinical assessments. participants will be asked about their health, diseases and habits including mental health questionnaires. participants must not be able to become pregnant if they want to participate in the study.


Eligibility criteria:
inclusion criteria: * female of non-childbearing potential, aged 18-65 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) between 25.0 and 39.9 kg/m\^2 (both inclusive). overweight should be due to excess adipose tissue, as judged by the investigator. exclusion criteria: * known or suspected hypersensitivity to trial products (including acetaminophen) or related products. * previous participation in this trial. participation is defined as signed informed consent. * previous participation in trial(s) with nnc0174-0833 unless documented that the subject was assigned to placebo treatment. participation is defined as randomised. * any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
multiple joint, structural barbell resistance exercise improves information processing speed

Conditions: Cognitive Decline; Aging

Summary: this study investigated the effect of acute multiple joint, structural barbell resistance exercise on information processing speed and conflict-related neural activity in older adults via a crossover, sham control, randomized control trial.


Eligibility criteria:
inclusion criteria: 1. male adults aged 50-65 years old 2. exercise ≥ 150 minutes/week 3. normal or corrected-to-normal vision 4. right-handed exclusion criteria: 1. dementia (mmse ≥ 24) 2. any medical condition listed on parq 3. depression (bdi-ii score ≤ 13) 4. any diagnostic cardiovascular, neurological and other chronic diseases

Keywords: exercise resistance training kinesiology cognition erp neuroimage
efficacy of manual toothbrushes in removing tooth stains

Conditions: Tooth Discoloration

Summary: efficacy of manual toothbrushes in removing tooth stains: a 6-week clinical research study.

the aim of this study is to evaluate the effectiveness of manual toothbrushes in reducing tooth staining after 6 weeks of unsupervised, daily use by participants.

Eligibility criteria:
inclusion criteria: * signed informed consent form; * male and female subjects, aged 18-70, inclusive; * good general health and good oral health based on the opinion of the study investigator; * presence of permanent natural anterior teeth (no veneers/crowns/restorations that may interfere with this study scoring procedures); * a minimum composite mean of 1.5 ≥ determined by the lobene tooth stain index; * available for the duration of the study; * clinical evidence of a tendency to form extrinsic stains on anterior teeth. exclusion criteria: * presence of orthodontic appliances/retainers involving scorable teeth; * presence of partial removable/fixed dentures and/or restorations involving scorable teeth; * tumor(s) of the soft or hard tissues of the oral cavity; * obvious signs of periodontal disease rampant caries, or any condition that the dental examiner considers exclusionary from the study; * five or more carious lesions requiring immediate care; * use of antibiotics, stain-inducing medications, and/or on any prescription that might interfere with the study outcome; * concurrent participation in another clinical study; * self-reported pregnancy and/or lactating women; * have used professional whitening product within one (1) year or had a dental prophylaxis (professional dental cleaning) within thirty (30) days - prior to the start of the study; * history of allergies to oral care/personal care consumer products or their ingredients; * history of alcohol and/or drug abuse.

Keywords: lobene tooth stain index
vitamin d supplementation and clinical outcomes in severe covid-19 patients

Conditions: Covid-19; Respiratory Distress Syndrome; Vitamin D Deficiency

Summary: single center, open label randomized clinical trial. study location: tertiary hospital center (university hospital split, croatia). all covid-19 patients with positive pcr test admitted to icu and in need for respiratory support will be eligible for inclusion in this study. patients admitted to icu with severe covid-19 disease and in need for invasive or non-invasive respiratory support with low levels of vitamin d (\<50 nmol/l) measured on admission. all patients are older than 18 years and have confirmed covid-19 disease with pcr test. intervention: all patients included in this study will receive standard of care. patients randomized into intervention group will be receiving 10 000 iu of cholecalciferol daily. supplement will be administered orally or via gastric tube during icu stay or for at least 14 days in case of icu discharge before day 14. supplementation will begin within 48 hours of admission to icu. supplement will be prepared and administered by experienced nursing staff. for patients receiving supplementation, vitamin d levels will be checked on days 7 and 14. in case that vitamin d levels are \> 150 nmol/l or if the calcium levels are consistently \> 2.6 mmol/l, further supplementation will be stopped. outcomes: primary outcome is number of days spent on ventilator. secondary outcomes: all-cause mortality on day 28, all-cause mortality on day 60, mortality at hospital discharge, clinical improvement at day 28 (who clinical progression scale), days spent in icu, days spent in hospital after discharge from icu, need for dialysis at day 28, bacterial superinfections, neutrophile to lymphocyte ratio, disease severity (crp levels, pao2/fio2 ratio, d-dimer levels, fibrinogen, ferritin, pct), adverse outcomes. hypothesis: patients receiving vitamin d supplementation will have shorter number of days spent on mechanical ventilation.


Eligibility criteria:
inclusion criteria: * patients admitted to icu with severe covid-19 disease and in need for invasive or non-invasive respiratory support with low levels of vitamin d (\<50 nmol/l) measured on admission. all patients are older than 18 years and have confirmed covid-19 disease with pcr test. exclusion criteria: * patients will be excluded from study in case of calcium levels that are consistently above normal serum range (\> 2.6 mmol/l, \> 10.5 mg/dl) or if vitamin d levels are \> 150 nmol/l.
nova max creatinine and egfr meter system

Conditions: Chronic Kidney Diseases; Acute Kidney Injury

Summary: to assess the performance of the nova max creatinine and egfr assay in the hands of clia-waived point-of-care users in at least three (3) distinct point-of-care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (the siemens exl creatinine determination). to assess the ease of use of the nova max creatinine and egfr meter system in the hands of the intended clia-waived point-of-care users.

this study is designed to evaluate the performance of the nm meter when used by cliaw operators in terms of both accuracy to an established reference method and precision. cliaw operators will receive no training or prompting on how to use the nm creatinine and egfr meter, operating only using the instructions found in printed labeling materials (ifu, qrg, packaging). in determining the accuracy of the device, subjects will be tested using the nm creatinine and egfr meter alongside a central laboratory reference method and the results will be compared to one another. this portion of the study is referred to as method comparison. in determining the precision of the device, multiple creatinine determinations will be made with the nm creatinine and egfr meter using both stabilized control materials (testing over the course of 20 days) and venous whole blood specimens (tested over the course of a single day). the difference between the multiple test results will determine the device's level of precision. this portion of the study is referred to as precision.

Eligibility criteria:
inclusion criteria: 1. adult males or females (≥ 18 years of age) 2. ckd stage 1 (healthy) 3. ckd stages 2-4 4. subjects willing and able to consent to participating in the study. 5. subjects whose pre-screen creatinine and egfr value, if performed, is deemed valuable to the study. exclusion criteria: 1. subjects unable to consent to participating in the study. 2. subjects possessing a cognitive disorder or other condition, which, in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study.

Keywords: egfr creatinine poct
collection of rna extracted from nasopharyngeal and saliva samples from same patients with suspicion of covid-19

Conditions: Respiratory Tract Infections

Summary: constitution of a collection of sars-cov-2 rna extracts from nasopharyngeal and saliva / sputum samples, from the same patients (paired samples), taken during the same consultation in an indication of detection of sars-cov-2 in with a view to developing tests / diagnostic tools for sars-cov-2.

in order to preserve their anonymity, the participant will be identified in a dedicated form by a unique identification number. an identification list of participants will be kept in the investigator's file. the investigator will ensure that the anonymity of each person participating in the research is guaranteed. the source documents are the original documents, data and files from which the data concerning the participant is reported in the data set_coll001.xls form provided to the investigator which will serve as an observation notebook. the investigator must agree to allow direct access to research source data during monitoring, audit or inspection visits. the source data is for the most part computerized and accessible after authorization. the data will be transcribed into an excel form data set_coll001.xls pseudonymized form which will serve as an observation book. the data will be recorded and then transmitted to id solutions via the data set_coll001.xls form provided to the investigator.

Eligibility criteria:
inclusion criteria: * male, female adult * patient with an indication for sars-cov-2 screening. * patient having been informed and having given his non-objection to participate in the study * patient affiliated with a french social security scheme or beneficiary of such a scheme exclusion criteria: * pregnant or breastfeeding women * vulnerable people adults placed under tutorship or curatorship or under judicial protection, patient unable to personally give consent, or adult protected by law, opposition expressed to inclusion in the study.

Keywords: sars-cov-2 saliva diagnostic
the value of 68ga-grazytracer pet in monitoring responses to immunotherapy of gastrointestinal malignancies

Conditions: Gastrointestinal Malignancies

Summary: this study aims to investigate the value of 68ga-grazytracer in predicting the efficacy of immunotherapy for gastrointestinal malignancies.

the investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. all participants will undergo a 68ga-grazytracer pet/ct after 3 cycles of immunotherapy to evaluate response. the imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.

Eligibility criteria:
inclusion criteria: 1. pathological and clinical diagnosis of gastrointestinal malignancies requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines. 2. signed and dated informed consent form. 3. commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. the patient is in good general condition with an expected survival of \> 6 months. 5. aged 18-75 years old. exclusion criteria: 1. patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. intestinal perforation, complete intestinal obstruction. 3. pregnant women and women who may be pregnant, women who are breastfeeding. 4. non-compliant person.

Keywords: 68ga-grazytracer pet/ct gastrointestinal malignancies immunotherapy
occlusal stabilization splints and sleep disordered breathing

Conditions: Sleep Bruxism

Summary: the purpose of this study is to investigate the effects of mandibular occlusal stabilization splint (oss) and modified farrar splint on sleep bruxism and respiratory indices and the effects of occlusal splints on the airway volume through imaging.


Eligibility criteria:
inclusion criteria: * diagnosed with sleep bruxism * prescribed an occlusal splint exclusion criteria: * less than 18 years old * secondary obstructive sleep apnea diagnosis * genetic disease that contributes to possible secondary obstructive sleep apnea * patient refuses to sign informed consent document * patient does not speak or read english * more than two missing posterior teeth (excluding third molars) * presence of gross malocclusion
pentoxifylline and late onset sepsis in preterm infants

Conditions: Neonatal Late Onset Sepsis

Summary: * hypothesis: the investigators hypothesized that pentoxifylline has potent anti-inflammatory effect which can augment the antimicrobial effect of antibiotics in treatment of late onset sepsis (los) in preterm infants thus decreasing neonatal mortality and morbidity. * the purpose of this study: to assess the efficacy and safety of pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity of preterm infants with los.

* role of pentoxifylline, a phosphodiesterase inhibitor, in reducing mortality associated with neonatal sepsis is not well studied. * hypothesis: we hypothesized that pentoxifylline has potent anti-inflammatory effect which can augment the antimicrobial effect of antibiotics in treatment of late onset sepsis (los) in preterm infants thus decreasing neonatal mortality and morbidity. * purpose of the study: to assess the efficacy and safety of pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity of preterm infants with los. * design: a prospective, randomized, double-blind clinical trial. * setting: neonatal intensive care unit, mansoura university children's hospital. * patients: 120 preterm infants with suspected or confirmed los. * intervention: enrolled infants were randomly assigned to receive intravenous pentoxifylline (5 mg/kg/hr for 6 hours on 6 successive days) or placebo in addition to antibiotics. * primary outcome: death before hospital discharge. * secondary outcomes: length of hospital stay, duration of respiratory support, duration of antibiotics use, chronic lung disease, necrotizing enterocolitis, intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, serum levels of tumor necrosis factor, c-reactive protein levels, and adverse effects of pentoxifylline.

Eligibility criteria:
inclusion criteria: - appropriate for gestational age preterm infants with suspected or confirmed late onset sepsis exclusion criteria: * preterm infants with major congenital malformations * preterm infants with chromosomal anomalies * preterm infants with inborn-errors of metabolism * preterm infants with congenital infection

Keywords: neonatal pentoxifylline randomized controlled trial
prospective validation of prostate biomarkers for repeat biopsy

Conditions: Prostate Cancer

Summary: target enrollment is 1000 prospectively enrolled subjects with an initial negative biopsy scheduled for repeat biopsy. subjects must have had their negative index prostate biopsy procedure within 30 months of being scheduled for their repeat biopsy. all enrolled subjects will have all core tissues from the initial negative biopsy blinded and tested with the assay. all subjects will have serum and plasma samples obtained prior to dre, and a urine sample collected immediately following dre but in advance of the repeat biopsy; samples will be blinded and sent to mdxhealth for evaluation.


Eligibility criteria:
inclusion criteria: * males, aged 40 years to 85, who underwent a previous cancer-negative prostate biopsy within 30 months of being scheduled for a repeat biopsy. * the initial trus guided negative prostate biopsy must have collected a minimum of 10 tissue cores and sections from all prostate biopsy cores collected by the physician must be submitted to mdxhealth in order to allow for full comprehensive testing/evaluation of all the sections of the patient's prostate prior to the scheduled repeat biopsy. * minimum tissue volume criteria of 20 microns of prostate biopsy core tissue is available (40 microns preferable). * previous biopsy histology may include the presence of high-grade prostatic intraepithelial neoplasia (hgpin), proliferative inflammatory atrophy (pia), glandular inflammation, atypical small acinar proliferation (asap) or atypical cells. * tissue was extracted using standard trus guided biopsy core extraction (and not transurethral resection of the prostate (turp). * pre-dre serum sample, pre-dre plasma sample, and post-dre urine sample to be collected in advance of the repeat biopsy. samples can be collected within three months of the scheduled repeat biopsy, up until the day of, but prior to, the procedure. exclusion criteria: * patient who has undergone previously testing by confirmmdx from the same biopsy * patients with prior diagnosis of prostate cancer in any previous biopsy. * patients with a limited life expectancy and generally not considered for a repeat tissue extracted using transurethral resection of the prostate (turp) procedures * patients with a history of cancer (except basal cell carcinoma)
minimally invasive open preperitoneal surgery with polysoft mesh versus a classic open surgery with light weight mesh

Conditions: Hernia, Inguinal

Summary: this is a prospective randomized study to evaluate the recovery of a hernia inguinalis by a minimally invasive open preperitoneal surgery with polysoft mesh versus a classic open surgery according to modified lichtenstein procedure with light weight mesh.


Eligibility criteria:
inclusion criteria: * symptomatic hernia inguinalis * \> 18 years

Keywords: hernia inguinalis
does pregabalin improve symptoms of anxiety in patients with epilepsy? a comparison with sertraline

Conditions: Epilepsy; Anxiety

Summary: the aim of the study is to compare the safety \& efficacy of sertraline (up to a dose of 200mg/day) \& pregabalin (up to a dose of 300mg/day) for the treatment of symptoms of anxiety in patients with epilepsy.

patients with epilepsy will be treated with either sertraline (up to a dose of 200mg/day) or pregabalin (up to a dose of 300mg/day) for the treatment of symptoms of anxiety. outcome measures will include changes in the anxiety severity scales.

Eligibility criteria:
inclusion criteria: * gad-7 total score above 10. * have a diagnosis of a partial seizure disorder. * have a hamilton-a total score 20 and above. * 18-80 years of age. * able to read at a fourth grade level. * if a woman of childbearing age, agrees to use an acceptable means of birth control. exclusion criteria: * unable to understand and sign a consent. * unable to follow instructions for the study. * displaying current suicidal ideation * having psychogenic non-epileptic seizures * have a history of drug or alcohol abuse. * use of any investigational drug within the last 30 days. * hypersensitivity reaction or other serious adverse event to pgb in prior trials.

Keywords: anxiety epilepsy